logo BDSP

Base documentaire

  1. Cost effectiveness of antenatal screening for cystic fibrosis. Commentary.

    Article - En anglais


    To estimate the cost effectiveness of different antenatal screening programmes for cystic fibrosis.

    Setting-Antenatal clinics and general practices in the United Kingdom.

    Design-Four components of the screening process were identified : information giving, DNA testing, genetic counselling, and prenatal diagnosis.

    The component costs were derived from the literature and from a pilot screening study in Yorkshire.

    The cost of a given screening programme was then obtained by summing the components according to the specific screening strategy adopted (sequential and couple), the proportion of carriers detected by the DNA test, and the uptake of screening.

    Baseline assumptions were made about the proportion with missing information on carrier status from previous pregnancies (20%), the proportion changing partners between pregnancies (20%), and the uptake of prenatal diagnosis (100%). Conclusions-While economic analysis cannot determine screening policy, the paper provides the NHS with the information on cost effectiveness needed to inform decisions on the introduction of a screening service for cystic fibrosis. involved, 2-4 antenatal screening has become feasible, and pilot studies show that it is generally acceptable in the United Kingdom. 5-9 Each health authority now needs to decide whether to introduce a service.

    One consideration will be cost effectiveness, and in this paper we estimate this for different screening strategies and under a range of assumptions.

    Mots-clés Pascal : Appareil digestif pathologie, Pancréas pathologie, Appareil respiratoire pathologie, Métabolisme pathologie, Economie santé, Maladie héréditaire, Dépistage, Exploration, Foetus, Homme, Mucoviscidose, Coût spécifique, Prénatal

    Mots-clés Pascal anglais : Digestive diseases, Pancreatic disease, Respiratory disease, Metabolic diseases, Health economy, Genetic disease, Medical screening, Exploration, Fetus, Human, Cystic fibrosis, Specific cost, Prenatal

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0042057

    Code Inist : 002B11D. Création : 01/03/1996.